- test performance
- state-transition
- calibration/validation
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- infectious diseases
- injuries/accidents
- health systems
- climate/environment
- culture/society
- economics/finance
- education/labor
- science/technology
- asia & pacific
Resources Repository
-
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Cost-Effectiveness Analysis | Calibration/Validation | Economics/Finance | Science/Technology | Asia & Pacific | Health Systems | Infectious Diseases | Mathematical Models | Microsimulation | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2008Health and Economic Impact of HPV 16 and 18 Vaccination and Cervical Cancer Screening in India
As cervical cancer is a leading cause of cancer death among women in low-income countries, …
As cervical cancer is a leading cause of cancer death among women in low-income countries, with approximately 25% of cases worldwide occurring in India, these authors estimated the potential health and economic impact of different cervical cancer prevention strategies in India. After empirically calibrating a cervical cancer model to country-specific epidemiologic data, they projected cancer incidence, life expectancy, and lifetime costs (I$2005), and calculated incremental cost-effectiveness ratios (I$/YLS) for the following strategies: pre-adolescent vaccination of…
Cost-Effectiveness Analysis | Calibration/Validation | Economics/Finance | Science/Technology | Asia & Pacific | Health Systems | Infectious Diseases | Microsimulation | Chronic Disease/Risk | Clinical Care | Health/Medicine -
ArticlePublication 2018Cost-Effectiveness of Strategies to Prevent Road Traffic Injuries in Eastern Sub-Saharan Africa and Southeast Asia: New Results from WHO-CHOICE
The authors applied a generalized cost-effectiveness analysis (GCEA) approach, applying a null reference case, in …
The authors applied a generalized cost-effectiveness analysis (GCEA) approach, applying a null reference case, in which the effects of currently implemented interventions were subtracted from current rates of burden, in order to identify the most efficient package of interventions that could be applied to Road Traffic Injuries (RTIs). They used a population model to estimate costs and effectiveness of interventions over a 100 year time frame in eastern sub-Saharan Africa and Southeast Asia. All heath…
Cost-Effectiveness Analysis | State-Transition | Culture/Society | Science/Technology | Asia & Pacific | Injuries/Accidents | Policy/Regulation | Sub-Saharan Africa -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | State-Transition | Economics/Finance | Asia & Pacific | Health Systems | Infectious Diseases | Health Outcomes | Dynamic Transmission | Microsimulation | Child/Nutrition | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Technology Assessment | Cost-Effectiveness Analysis | Climate/Environment | Economics/Finance | Asia & Pacific | Infectious Diseases | Costing Methods | Health Outcomes | Mathematical Models | Chronic Disease/Risk | Social Determinants | Environmental Health | Policy/Regulation | Health/Medicine | Global | Sub-Saharan Africa -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Climate/Environment | Economics/Finance | Asia & Pacific | Health Systems | Infectious Diseases | Mathematical Models | Dynamic Transmission | Child/Nutrition | Global Governance | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2016Rotavirus Vaccines Contribute Towards UHC in A Mixed Public–Private Healthcare System
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from …
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from the household’s perspective. The authors found that rotavirus vaccination reduces rotavirus episodes and expenditure substantially and provides financial risk protection to all income groups. Although the rich are paying more out of pocket than the poor by utilizing more expensive healthcare, the poor are paying more in proportion to household income. Poverty reduction benefits are concentrated amongst the poorest two…
Cost-Effectiveness Analysis | Economics/Finance | Science/Technology | Asia & Pacific | Health Systems | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Child/Nutrition | Social Determinants | Health/Medicine -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Economics/Finance | Science/Technology | Asia & Pacific | Health Systems | Infectious Diseases | Costing Methods | Health Outcomes | Chronic Disease/Risk | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Technology Assessment | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific | Health Systems | Priority Setting/Ethics | Policy/Regulation | Government/Law | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean